|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
SE8804164A0
(sv)
|
1988-11-17 |
1990-05-18 |
Per Prisell |
Farmaceutisk beredning
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5177197A
(en)
|
1990-02-27 |
1993-01-05 |
Ludwig Institute For Cancer Research |
Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
|
|
US5229495A
(en)
|
1991-06-18 |
1993-07-20 |
Ludwig Institute For Cancer Research |
Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
DK0662146T3
(da)
|
1992-09-03 |
2000-11-13 |
Univ California |
Dorsalvævpåvirkende faktor og præparat
|
|
US5453492A
(en)
|
1993-07-28 |
1995-09-26 |
La Jolla Cancer Research Foundation |
60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
|
|
JPH09512910A
(ja)
|
1994-05-04 |
1997-12-22 |
マウント・サイナイ・ホスピタル・コーポレイション |
ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
|
|
US5616561A
(en)
|
1995-03-31 |
1997-04-01 |
Regents Of The University Of California |
TGF-β antagonists as mitigators of radiation-induced tissue damage
|
|
NZ500577A
(en)
|
1997-04-29 |
2001-02-23 |
Regeneron Pharma |
Human cerberus protein that regulates cell function, induce neural development or antagonise bone morphogenic proteins
|
|
CA2292899A1
(en)
|
1997-06-06 |
1998-12-10 |
Regeneron Pharmaceuticals, Inc. |
Ntn-2 member of tnf ligand family
|
|
US5935852A
(en)
|
1997-07-03 |
1999-08-10 |
Genetics Institute, Inc. |
DNA molecules encoding mammalian cerberus-like proteins
|
|
AU4409899A
(en)
|
1998-05-28 |
1999-12-13 |
Board Of Trustees Of The University Of Arkansas, The |
Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
|
|
WO2000022909A2
(en)
|
1998-10-19 |
2000-04-27 |
Biotech Australia Pty. Limited |
Systems for oral delivery
|
|
CN101469329B
(zh)
|
1998-11-27 |
2012-10-24 |
达尔文发现有限公司 |
增加骨矿化的组合物和方法
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
WO2000055193A2
(en)
|
1999-03-12 |
2000-09-21 |
Regeneron Pharmaceuticals, Inc. |
Human dan/cerberus related protein 6 (dcr6)
|
|
US7358056B1
(en)
|
1999-08-30 |
2008-04-15 |
Signal Pharmaceuticals |
Methods for modulating signal transduction mediated by TGF-β and related proteins
|
|
WO2001047944A2
(en)
|
1999-12-28 |
2001-07-05 |
Curagen Corporation |
Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
|
|
AU2001236519A1
(en)
|
2000-01-24 |
2001-07-31 |
Millennium Pharmaceuitcals, Inc. |
Identification, assessment, prevention, and therapy of prostate cancer
|
|
AU2001229508A1
(en)
|
2000-01-31 |
2001-08-07 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
AU2001236589A1
(en)
|
2000-02-04 |
2001-08-14 |
Aeomica, Inc. |
Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
|
|
US20040087016A1
(en)
|
2000-05-12 |
2004-05-06 |
University Of Utah Research Foundation |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
AU6459801A
(en)
|
2000-05-12 |
2001-11-26 |
Mark T Keating |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
US20020106650A1
(en)
|
2000-06-01 |
2002-08-08 |
Paszty Christopher J. |
Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
|
|
AU2001272482A1
(en)
|
2000-06-19 |
2002-01-02 |
F.Hoffmann-La Roche Ag |
Osteolevin gene polymorphisms
|
|
EP1370287A2
(en)
|
2000-12-01 |
2003-12-17 |
Wyeth |
Method and composition for modulating bone growth
|
|
WO2002054940A2
(en)
|
2001-01-12 |
2002-07-18 |
University Of Medicine & Dentistry Of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
|
JP2005511593A
(ja)
|
2001-11-08 |
2005-04-28 |
メルク エンド カムパニー インコーポレーテッド |
骨粗鬆症を治療するための組成物及び方法
|
|
EP1504099A4
(en)
|
2001-12-10 |
2006-05-10 |
Nuvelo Inc |
NEW NUCLEIC ACIDS AND POLYPEPTIDES
|
|
GB0130738D0
(en)
|
2001-12-21 |
2002-02-06 |
Serono Internat S A |
Protein
|
|
GB2385052A
(en)
|
2002-02-05 |
2003-08-13 |
Leuven K U Res & Dev |
Treatment of spondyloarthropathies
|
|
US20030186915A1
(en)
|
2002-02-11 |
2003-10-02 |
Yang Pan |
Regulatory polynucleotides and uses thereof
|
|
JP2005253301A
(ja)
|
2002-02-20 |
2005-09-22 |
Taisho Pharmaceut Co Ltd |
骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
|
|
EP1575481A4
(en)
|
2002-03-01 |
2010-01-06 |
Celltech R & D Inc |
PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
|
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
|
CA2486113A1
(en)
|
2002-05-17 |
2003-12-04 |
Wyeth |
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
|
|
AU2003276430A1
(en)
|
2002-06-14 |
2003-12-31 |
Stowers Institute For Medical Research |
Wise/sost nucleic acid sequences and amino acid sequences
|
|
WO2004041277A1
(en)
|
2002-11-01 |
2004-05-21 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
US20060276385A1
(en)
|
2003-01-13 |
2006-12-07 |
Hanjoong Jo |
Anti-inflammatory agents and methods of their use
|
|
WO2004082608A2
(en)
|
2003-03-14 |
2004-09-30 |
Celltech R & D, Inc. |
Ligands for tgf-beta binding proteins and uses thereof
|
|
AU2004238238C1
(en)
|
2003-05-07 |
2010-01-14 |
Merck Sharp & Dohme Corp. |
Androgen receptor modulators and methods of use thereof
|
|
CN1835974A
(zh)
|
2003-06-16 |
2006-09-20 |
细胞技术研究与发展公司 |
对硬化素特异的抗体和用于增加骨矿化的方法
|
|
WO2005023311A2
(en)
|
2003-09-11 |
2005-03-17 |
Association Francaise Retinitis Pigmentosa (Afrp) |
Novel targets for the treatment of retina diseases
|
|
US8461155B2
(en)
|
2003-09-22 |
2013-06-11 |
University Of Connecticut |
Sclerostin and the inhibition of WNT signaling and bone formation
|
|
EP1670425A4
(en)
|
2003-10-07 |
2008-04-16 |
Quark Pharmaceuticals Inc |
BONE MORPHOGENETIC PROTEIN (BMP) 2A AND ITS APPLICATIONS
|
|
CA2566746A1
(en)
|
2004-05-14 |
2005-12-01 |
Baylor College Of Medicine |
Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
|
|
JP2008509087A
(ja)
|
2004-05-27 |
2008-03-27 |
アクセルロン ファーマ インコーポレーテッド |
Ｔｇｆ抑制解除因子およびそれに関連する使用方法
|
|
EP1863340A2
(en)
|
2005-03-11 |
2007-12-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US20060293667A1
(en)
|
2005-05-19 |
2006-12-28 |
Agnes Vignery |
Bone implant device and methods of using same
|
|
WO2006135734A2
(en)
|
2005-06-10 |
2006-12-21 |
The Regents Of The University Of California |
Compositions and methods for altering bone density and bone patterning
|
|
EP1981910B1
(en)
|
2006-01-13 |
2013-06-26 |
A Chan Holding B.V. |
Method for identifying inhibitor of the glypican-sclerostin interaction
|
|
EP2097450A2
(en)
|
2006-11-10 |
2009-09-09 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
EP2094731A2
(en)
|
2006-11-10 |
2009-09-02 |
UCB Pharma S.A. |
Anti human sclerostin antibodies
|
|
PL3345607T3
(pl)
|
2006-12-29 |
2023-01-09 |
Ossifi-Mab Llc |
Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
US20110044978A1
(en)
|
2007-12-14 |
2011-02-24 |
Amgen Inc. |
Method for treating bone fracture
|
|
WO2010100200A2
(en)
*
|
2009-03-05 |
2010-09-10 |
Novartis Ag |
Lyophilised antibody formulation
|
|
WO2010115932A1
(en)
*
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
US9617323B2
(en)
|
2010-06-07 |
2017-04-11 |
Joshua Rabbani |
Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
|
|
ES2863626T3
(es)
|
2010-10-27 |
2021-10-11 |
Amgen Inc |
Anticuerpos DKK1 y métodos de uso
|
|
EP2681242B1
(en)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin and dkk-1 bispecific binding agents
|
|
MX338078B
(es)
|
2011-03-25 |
2016-04-01 |
Amgen Inc |
Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
|
|
SMT202000494T1
(it)
|
2011-04-19 |
2020-11-10 |
Amgen Inc |
Metodo per il trattamento dell'osteoporosi
|
|
LT2739311T
(lt)
|
2011-08-04 |
2018-06-11 |
Amgen Inc. |
Kaulų tarpų defektų gydymo būdas
|
|
WO2013101451A1
(en)
|
2011-12-28 |
2013-07-04 |
Amgen Inc. |
Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
|
|
CN104619342A
(zh)
|
2012-07-05 |
2015-05-13 |
Ucb医药有限公司 |
骨疾病的治疗
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
WO2017027861A1
(en)
|
2015-08-13 |
2017-02-16 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
KR20190037261A
(ko)
|
2016-08-08 |
2019-04-05 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
|
|
JP2020502218A
(ja)
|
2016-12-21 |
2020-01-23 |
メレオ バイオファーマ ３ リミテッド |
骨形成不全症の処置における抗スクレロスチン抗体の使用
|
|
KR20220051269A
(ko)
|
2016-12-21 |
2022-04-26 |
메레오 바이오파마 3 리미티드 |
불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
|
|
EP3596225A1
(en)
|
2017-03-14 |
2020-01-22 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
KR20200034748A
(ko)
|
2017-07-27 |
2020-03-31 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
Sost 항체 약학적 조성물 및 그의 용도
|
|
CN111954719B
(zh)
|
2018-03-26 |
2025-07-18 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型
|
|
IL316596A
(en)
|
2018-03-30 |
2024-12-01 |
Amgen Inc |
C-terminal antibody variants
|
|
JP7425041B2
(ja)
|
2018-08-10 |
2024-01-30 |
アムジエン・インコーポレーテツド |
抗体医薬製剤を作製する方法
|